MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Kodu・Aktsiate loetelu・uniQure NV

uniQure NV

Avatud

21.82 -2.59

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

21.56

Max

22.32

Põhinäitajad
By Trading Economics
Sissetulek	-43M -81M
Müük	-1.6M 3.7M
Kasumimarginaal	-2,175.871
Töötajad	209
EBITDA	-7.7M -52M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+125.18% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-690M 1.4B
Eelmine avamishind	24.41
Eelmine sulgemishind	21.82

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

10.05 / 14.75 Toetus ja vastupanu

uniQure NV Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. jaan 2026, 15:14 UTC

Suurimad hinnamuutused turgudel

UniQure Climbs on Scheduling FDA Meeting for Huntington's Disease Treatment

3. nov 2025, 13:34 UTC

Suurimad hinnamuutused turgudel

UniQure Shares Sink After Negative FDA Response to Huntington's Disease Treatment

24. sept 2025, 18:51 UTC

Tulu

These Stocks Are Moving the Most Today: Alibaba, Micron, Lithium Americas, Freeport-McMoRan, uniQure, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

uniQure NV Prognoos

Hinnasiht

By TipRanks

125.18% tõus

12 kuu keskmine prognoos

Keskmine 50.44 USD 125.18%

Kõrge 70 USD

Madal 33 USD

Põhineb 11 Wall Streeti analüütiku instrumendi uniQure NV 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

11 ratings

Osta

Hoia

Müü

Põhineb 11 analüütiku instrumendi uniQure NV aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

10.05 / 14.75Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.